Abstract:PURPOSE:A new chemotherapy regimen was designed for leukemia to improve response to therapy and elucidate the possible underlying mechanisms responsible for its efficacy.METHODS:Cells of the chronic myelogenous leukemia (CML) cell line, K562, were treated singly, in combination, and in sequence with clinically equivalent dosages of topotecan, which targets topoisomerase I (Topo I), and etoposide and mitoxantrone, which target topoisomerase II (Topo II), to determine the best treatment. Apoptosis, early cell deaths, and cell cytotoxicities in drug-treated cells were determined with annexin V and propidium iodide staining and MTT assays, respectively. Confocal microscopy and RT-PCR showed the cellular locations and relative increases in Topo IIalpha in topotecan-treated cells. The double comet assay of individual cells showed simultaneously free Topo proteins, non-Topo-associated DNA, and Topo-DNA complexes in drug-induced DNA fragments.RESULTS:Sequential treatment with topotecan on days 1-3, followed by etoposide+mitoxantrone on days 4, 5, 9 and 10 resulted in 100% cell death whereas treatments involving administration of drugs singly or simultaneously resulted in less cell kill. The cytotoxicity results in cells treated for fewer days with the same sequential chemotherapy regimen showed the same trend, and adequate surviving cells for the experiments on the cellular and molecular mechanisms of drug action were produced. An increase in Topo IIalpha mRNA from RT-PCR 1 h after topotecan treatment was observed. Observations on K562 cells treated sequentially with topotecan followed by etoposide, mitoxantrone or etoposide+mitoxantrone were as follows: (1) Topo IIalpha protein levels increased and relocated from the cytoplasm into the nucleus as detected by confocal microscopy, (2) Topo IIalpha-DNA complexes increased and were associated with fragmented DNA (positive double comets) as detected by protein-DNA double comet assay, and (3) Topo I and Topo IIbeta proteins were not associated with fragmented DNA. Topotecan-induced Topo IIalpha protein levels correlated with increased numbers of positive double comets and reduction of cell viability.CONCLUSIONS:Our results showed that Topo IIalpha protein induction after Topo I-directed drug treatment enhanced the sensitivity of cells to subsequent exposure to Topo II-directed drugs. Timed sequential chemotherapy with topotecan followed by etoposide+mitoxantrone is an effective regimen to ablate CML cancer cells.

P5-13-13: the Role of Topoisomerase IIa in Predicting Sensitivity to Anthracyclines in Breast Cancer Patients: A Meta-Analysis of Published Literatures.

The Role of Topoisomerase IIα in Predicting Sensitivity to Anthracyclines in Breast Cancer Patients: a Meta-Analysis of Published Literatures

The Role Of Topoisomerase Ii Alpha In Predicting Sensitivity To Anthracyclines In Breast Cancer Patients: A Meta-Analysis Of Published Literatures

The Research Progress of the Association Between DNA Topoisomerase IIα(topo IIα) and Sensitivity to Chemotherapy for Breast Cancer

The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.

A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

Impact of topoisomerase IIα overexpression in the primary colon tumor on the prognosis of metastatic colorectal cancer

Differential Expression of the Topoisomerase IIα and Β Genes in Human Breast Cancers

Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study

Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.

Oncogenic role and potential regulatory mechanism of topoisomerase IIα in a pan-cancer analysis

Relationship Between Expression of Topoisomerase II Isoforms and Intrinsic Sensitivity to Topoisomerase II Inhibitors in Breast Cancer Cell Lines

Oncogenic role and potential regulatory mechanism of topoisomerase II in a pan-cancer analysis

Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience

Relationship Between Expression of Topoisomerase II Isoforms and Chemosensitivity in Choroidal Melanoma.

Topotecan-induced Topoisomerase IIalpha Expression Increases the Sensitivity of the CML Cell Line K562 to Subsequent Etoposide Plus Mitoxantrone Treatment.

Prognostic Significance of DNA Topoisomerase II Alpha (TOP2A) in Cholangiocarcinoma

Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen

Correlation between the Expression of Topo IIα and Ki67 in Breast Cancer and its clinical Pathological characteristics